Clinical Trial: Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07621718) titled 'Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )' on May 26.

Brief Summary: The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

Study Start Date: May 22

Study Type: INTERVENTIONAL

Condition: Pancreatic Cancer Pancreatic Cancer Metastatic PDAC PDAC - Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma (PDAC) Pancreatic Adenocarcinom...